Monopar Therapeutics Inc. (MNPR) analyst actions
Rating and price-target actions on MNPR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MNPR overview →
3 measured MNPR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease | Press release | +0.00% | -0.49% | |
| Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers | Press release | +3.63% | +12.39% | |
| Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients | Press release | +5.37% | +5.13% |
Keep exploring
More MNPR: earnings → · SEC filings → · MNPR overview →